Switzerland· 55184001
Remicade, Lyophilisat
A infliximab product containing infliximabum, registered in Switzerland by Janssen-Cilag AG and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Infliximab is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AB02 (infliximab), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 9 of them publish a price we can compare per daily dose
Infliximab · ATC L04AB02
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of infliximab costs, country by country.
Normalised to the WHO defined daily dose (3.75 mg), the median price runs from $0.31 in Finland to $24.45 in Switzerland — a ×79 gap.
- Switzerland: $24.45 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Infliximab · price per daily dose (3.75 mg)
USD · FX 28 Sept 2026
- CH Switzerland$24.45
- FI Finland$0.31
The record
At a glance
Swissmedic (Switzerland)- Active substance
- infliximabum
- Manufacturer
- Janssen-Cilag AG
- Country
- Switzerland (CH)
- ATC code
- L04AB02
- ATC class
- Infliximab
- Defined daily dose
- 3.75 mg, P
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680551840015Durchstf 1 StkCHF 565.5
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
443 interactions on record for infliximab.
Graded by severity as the source publishes them — 290 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Infliximab · interactions on record
443 records
- 290 severe
- 146 moderate
- 7 minor
Most severe, free to view
- PrednisoloneA07EA01severe
- HydrocortisoneA07EA02severe
- PrednisoneA07EA03severe
- BetamethasoneA07EA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Infliximab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaFLIXABISamsung Bioepis NL B.V., Delft
- FinlandFlixabiSAMSUNG BIOEPIS NL B.V.
- United StatesAVSOLAAmgen, Inc
- BelgiumFlixabi 100 mgSamsung Bioepis NL
- SpainFLIXABI 100MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONSamsung Bioepis Nl B.V.
- PolandFlixabiSamsung Bioepis NL B.V.
- United KingdomFlixabi 100mg powder for concentrate for solution for infusion vialsBiogen Idec Ltd
- IrelandFlixabi 100 mg powder for concentrate for solution for infusionSamsung Bioepis NL B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Remicade, Remsima
- Liechtenstein · Remicade, Remsima
- Norway · Remicade, Remsima
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/322b9aea-0993-4701-9a05-9212b879e69a GET /v1/drugs/322b9aea-0993-4701-9a05-9212b879e69a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "infliximabum 100 mg",
"valid_from": "2000-07-01",
"limitations": "[{\"description\":\"Die Behandlung mit REMICADE bedarf der Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes.<br>\\n<br>\\n<b>Aktive Rheumatoide Arthritis</b><br>\\nBehandlung der aktiven rheumatoiden Arthritis, wenn die vorausgegangene antirheumatische Standardtherapie mit krankheitsmodifizierenden Antirheumatika (DMARDs) unzulänglich war.<br>\\n<br>\\n<b>Morbus Crohn</b><br>\\nBehandlung von Patienten mit aktivem Morbus Crohn, wenn die vorausgegangene konventionelle Therapie (z.B. mit Azathioprin, 6-Mercaptopurin, Steroiden) unzulänglich war.<br>\\n<br>\\n<b>Morbus Bechterew/Ankylosierende Spondylitis</b><br>\\nBehandlung des Morbus Bechterew, wenn die vorausgegangene konventionelle Therapie unzulänglich war.<br>\\n<br>\\n<b>Moderate bis schwere Colitis ulcerosa</b><br>\\nBehandlung erwachsener Patienten mit REMICADE, wenn die vorausgegangene konventionelle Therapie (z.B. mit Azathioprin, 6-Mercaptopurin oder Glukokortikoiden) unzulänglich war oder nicht vertragen wurde.<br>\\n<br>\\nDie Verschreibung von REMICADE für die folgenden Behandlungen kann nur durch Fachärzte der Rheumatologie/Dermatologie oder rheumatologische/dermatologische Universitätskliniken/Polikliniken erfolgen:<br>\\n<br>\\n<b>Schwere Plaque-Psoriasis</b><br>\\nBehandlung erwachsener Patienten mit schwerer Plaque-Psoriasis, bei denen 1.) eine Phototherapie oder eine der folgenden konventionellen systemischen Therapien (Ciclosporin, Methotrexat, Acitretin) keinen therapeutischen Erfolg gezeigt haben, und 2.) eine TNF- alpha blockierende Substanz (z.B. Etanercept) keinen therapeutischen Erfolg gezeigt hat. Falls nach 14 Wochen kein therapeutischer Erfolg eingetreten ist, ist die Behandlung abzubrechen. Die maximale Behandlungsdauer beträgt 1 Jahr. <br>\\n<br>\\n<b>Psoriasis Arthritis</b><br>\\nBehandlung erwachsener Patienten mit aktiver Psoriasis-Arthritis 1.) nur in Kombination mit Methotrexat, bei Versagen von mindestens zwei krankheitsmodifizierenden DMARD inklusive Methotrexat und 2.) nach Versagen der Kombinationen Methotrexat/Etanercept oder Methotrexat/Adalimumab.<br>\\n<br>\\n\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2021-08-01\"}]",
"galenic_form": "Trockensub 100 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2000-07-01",
"self_retention_pct": 10
}See everything about infliximab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.